SOBI.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 Apr 2024 @ 11:29):

Stats
Today's Volume	221 973
Average Volume	535 246
Market Cap	86.91B
EPS	SEK0 ( 2024-02-07 )
Next earnings date	( SEK2.16 ) 2024-04-24
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	34.61
ATR14	SEK0.161 (0.06%)

Volume Correlation

Long: -0.06 (neutral)

Short: -0.91 (very strong negative)

Signal:(43.941) Neutral

Swedish Orphan Biovitrum Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Swedish Orphan Biovitrum Correlation - Currency/Commodity

0.22
( neutral )

0.35
( neutral )

0.00
( neutral )

-0.14
( neutral )

0.39
( neutral )

0.01
( neutral )

Swedish Orphan Biovitrum Financials

Annual	2023
Revenue:	SEK22.12B
Gross Profit:	SEK14.05B (63.52 %)
EPS:	SEK7.47

Q4	2023
Revenue:	SEK6.84B
Gross Profit:	SEK4.46B (65.15 %)
EPS:	SEK3.02

Q3	2023
Revenue:	SEK5.17B
Gross Profit:	SEK4.00B (77.40 %)
EPS:	SEK0.300

Q2	2023
Revenue:	SEK4.87B
Gross Profit:	SEK3.50B (71.84 %)
EPS:	SEK0.710

Financial Reports:

No articles found.

Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.